

1 Pathogens detected using a syndromic molecular diagnostic platform in patients hospitalized
2 with severe respiratory illness in South Africa in 2017

3 Malefu Moleleki^{1,2#}, Mignon du Plessis^{1,2}, Kedibone Ndlangisa^{1,2}, Cayla Reddy^{1,2}, Anne von
4 Gottberg^{1,2}, Orienka Hellferscee^{1,3}, Omphe Mekgoe⁴, Meredith McMorrow^{5,6}, Sibongile
5 Walaza^{1,7}, Cheryl Cohen^{1,7}, Stefano Tempia^{1,5,6,7,8}, Ebrahim Variava^{9,10}, Nicole Wolter^{1,2}

6 ¹Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases
7 of the National Health Laboratory Service, Johannesburg, South Africa.

8 ²Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of
9 Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

10 ³Department of Medical Virology, School of Pathology, Faculty of Health Sciences,
11 University of the Witwatersrand, Johannesburg, South Africa

12 ⁴Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand,
13 Johannesburg, South Africa

14 ⁵Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
15 of America

16 ⁶Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

17 ⁷School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
18 Johannesburg, South Africa

19 ⁸MassGenics, Duluth, Georgia, United States of America

20 ⁹Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand,
21 Johannesburg, South Africa

22 ¹⁰Perinatal HIV Unit, Faculty of Health Sciences, University of the Witwatersrand,
23 Johannesburg, South Africa

24

25 #Corresponding author: Malefu Moleleki[†], malefum@sun.ac.za

26

27

28 Keywords: severe respiratory illness, community-acquired pneumonia, Taqman array card,
29 real-time polymerase chain reaction

30

31

32

33

34

35 Word count Abstract: 250

36 Word count Main Text: 2702

37

[†] Present address: Division of Medical Microbiology and Immunology; Faculty of Health Sciences; Stellenbosch University; NHLS Tygerberg Hospital; Cape Town; South Africa

38 **Abstract**

39 **Background**

40 Pneumonia continues to be a leading cause of death globally; however, in >50% of cases, an
41 etiological agent is not identified. We describe the use of a multi-pathogen platform, TaqMan
42 array card (TAC) real-time PCR, for the detection of pathogens in patients hospitalized with severe
43 respiratory illness (SRI).

44

45 **Methods**

46 We conducted prospective hospital-based surveillance for SRI among patients at two sentinel
47 sites in South Africa between January and December 2017. Patients were included in this study
48 if a blood specimen and at least one respiratory specimen (nasal- and oro-pharyngeal (NP/OP)
49 swabs and/or sputum) were available for testing. We tested respiratory specimens for 21
50 respiratory pathogens and blood samples for nine bacteria using TAC. Pathogen detection was
51 compared by age group and HIV status using the chi-squared test.

52

53 **Results**

54 During 2017, 956 patients were enrolled in SRI surveillance, and of these, 637 (67%) patients
55 were included in this study (637 blood, 487 NP/OP and 411 sputum specimens tested). At least
56 one pathogen was detected in 83% (527/637) of patients. Common pathogens detected included
57 *H. influenzae* (225/637; 35%), *S. pneumoniae* (224/637; 35%), rhinovirus (144/637; 23%), *S.*
58 *aureus* (129/637; 20%), *K. pneumoniae* (85/637; 13%), *M. tuberculosis* (75/637; 12%), and

59 respiratory syncytial virus (57/637; 9%). Multiple pathogens (≥ 2) were co-detected in 57%
60 (364/637) of patients.

61 **Conclusion**

62 While use of a multi-pathogen platform was useful in the detection of a pathogen in the
63 majority of the patients, pathogen co-detections were common and would need clinical
64 assessment for usefulness in individual-level treatment and management decisions.

65

66 **Background**

67 Worldwide, pneumonia remains the leading cause of morbidity and mortality in children aged
68 <5 years, accounting for 16% of all deaths between 2000 and 2016 (1). This burden is
69 geographically disproportionate: low and middle-income countries accounted for 89% of the
70 estimated 336 million pneumonia cases in all ages in 2016, and 62% of the estimated 2 million
71 pneumonia deaths occurred in sub-Saharan Africa and South Asia (2). HIV infection is an
72 important risk factor for pneumonia, specifically in South Africa where HIV prevalence among
73 individuals hospitalized with pneumonia can be up to 74% in patients aged ≥ 5 years and 90% in
74 adults aged 25–44 years (3, 4). Rapid identification of the etiological agent would allow for
75 pathogen-directed treatment, in line with current antibiotic stewardship practices (5).

76 Conventional microbiological testing for pneumonia-causing pathogens involves use of culture,
77 microscopy, antigen-antibody tests and pathogen-specific polymerase chain reaction (PCR) (6)
78 assays (7–9). Through the severe respiratory illness (SRI) surveillance programme in South
79 Africa, the etiology of community-acquired pneumonia for selected pathogens, namely
80 influenza A and B viruses, parainfluenzavirus (PIV) 1–3, respiratory syncytial virus (RSV),
81 enterovirus, human metapneumovirus (hMPV), adenovirus, human rhinovirus and
82 *Streptococcus pneumoniae* using individual real-time PCR assays has been described (3, 4).

83 However, a pathogen remained undetected in more than 50% of patients (3, 4). Multi-pathogen
84 real-time PCR platforms may improve the detection of pathogens when compared to
85 conventional tests (10, 11), and potentially highlight important roles of other pneumonia-
86 causing pathogens in the era of the pneumococcal conjugate and *Haemophilus influenzae* type
87 b vaccines (12, 13). In this study, we describe the use of the multi-pathogen platform, TaqMan

88 array card (TAC) real-time PCR system, for the detection of pathogens in patients hospitalized
89 with SRI.

90 **Materials and Methods**

91 **Study population**

92 Prospective hospital-based syndromic surveillance for SRI was initiated in 2009 in South Africa
93 to describe the etiology of and risk factors for community-acquired pneumonia as previously
94 described (14). Cases enrolled at two sentinel sites hospitals in the per-urban area of the North-
95 West Province and a rural area of Mpumalanga Province in South Africa between January and
96 December 2017 were included in the current study.

97 Case definition

98 A case of SRI was defined according to an adapted World Health Organization (WHO) case
99 definition (14). Briefly, SRI was defined as any hospitalized individual, regardless of symptom
100 duration, in age-defined categories as follows: any child aged 2 days to <3 months with
101 diagnosis of suspected sepsis or physician diagnosed lower respiratory tract infection (LRTI)
102 irrespective of signs and symptoms, any child ≥ 3 months to <5 years with physician-diagnosed
103 acute LRTI including bronchiolitis, pneumonia, bronchitis and pleural effusion, and for older
104 children aged ≥ 5 years and adults, as measured fever ($>38^{\circ}\text{C}$) or reported fever and cough. All
105 SRI cases with ≥ 10 days symptom duration were classified as chronic SRI. Surveillance officers
106 administered a questionnaire with demographic information and obtained clinical information
107 from medical records. In the event that routine HIV testing was not done, HIV testing was

108 performed at National Institute for Communicable Diseases (NICD) in Johannesburg, South
109 Africa as previously described (4).

110 **Specimen collection**

111 Nasopharyngeal aspirates were collected from children aged <5 years and combined naso- /
112 oro-pharyngeal (NP/OP) swabs from patients aged ≥5 years. Induced sputum specimens were
113 collected from individuals aged ≥3 months. If induced sputum collection was contraindicated or
114 was not advised by the attending clinician and a patient was able to expectorate, expectorated
115 sputum was collected. Whole blood was collected from patients of all ages. Specimens were
116 transported to the NICD for testing and thereafter stored at -80°C.

117 **Laboratory testing**

118 Individual real-time PCR (IRTP) testing of SRI specimens

119 Total nucleic acid (15) was extracted from 200 µl each of blood, NP/OP and sputum using the
120 Roche MagNA Pure 96 automated extractor (Roche Diagnostics, Mannheim, Germany) with the
121 DNA and Viral Nucleic Acid Small Volume kit according to manufacturer's instructions. In-house
122 real-time PCR assays were carried out for the detection of *S. pneumoniae* in blood and
123 *Bordetella* spp. (*B. pertussis*, *B. parapertussis* and *B. holmesii*) in NP/OP and sputum specimens
124 (16, 17). A commercial Fast-Track Diagnostics FLU/HRSV real-time PCR kit (Fast-Track
125 Diagnostics, Esch-sur-Alzette, Luxembourg) was used for the detection of influenza A viruses,
126 influenza B viruses and respiratory syncytial virus in NP/OP specimens as previously described
127 (18).

128 TAC testing

129 A total of 956 patients were enrolled in the SRI surveillance program, of which 637 were
130 included in this study if a blood specimen and at least one respiratory specimen (naso- and oro-
131 pharyngeal (NP/OP) swabs and/or sputum) were available for testing. From these patients, we
132 tested any left-over specimens with sufficient volume: 200 µl for NP/OP and sputum specimens
133 , and any volume for blood specimens (Fig 1).

134 Nucleic acid extraction for TAC testing

135 An aliquot of 300 µl whole blood was incubated at 37°C for 60 min with an enzyme lysis
136 solution (1.5 mg/mL lysostaphin, 2500 U/mL mutanolysin, and 200 mg/mL lysozyme (Sigma-
137 Aldrich, St. Louis, MO, USA) in TE buffer prior to extraction (19). TNA was extracted using the
138 MagNA Pure Compact instrument (Roche Diagnostics) with Total Nucleic Acid Isolation Kit I
139 according to the manufacturer's instructions. TNA was extracted from 200 µl of NP/OP and
140 sputum specimens using the Roche MagNA Pure 96 automated extractor (Roche Diagnostics)
141 with the DNA and Viral Nucleic Acid Small Volume kit according to manufacturer's instructions.

142 TAC design

143 TaqMan Array Cards were adapted from previously published assays (11, 19, 20). Table S1 lists
144 the organisms tested on the blood and respiratory TACs in this study. All targets were detected
145 in two replicates on the respiratory TAC or four replicates on the blood TAC with the exception
146 of *H. influenzae*, which was detected in two replicates on the blood TAC. Cards included two

147 controls, namely -the internal positive control (IPC) for monitoring of the real-time PCR reaction
148 and a human RNaseP gene control for monitoring of specimen quality.

149 TAC real-time PCR

150 Whole bloods were tested using the blood TAC while NP/OP specimens and sputum were
151 tested using the respiratory TAC as previously described (19). Briefly, TAC assays were
152 performed using 50 µl qScript XLT 1-step RT-qPCR Toughmix (Quantabio, Beverly,
153 Massachusetts, USA) and 50 µl of TNA extract. TAC PCR was carried out on the Applied
154 Biosystems ViiA7 and QuantStudio 7 Real Time PCR systems (Life Technologies, New York, USA)
155 using the following cycling conditions: 45 °C for 10 min, 94 °C for 10 min, 45 cycles of 94 °C for
156 30 sec and 60 °C for 1 min. A no template control (NTC) and positive control consisting of
157 combined RNA transcripts generated as previously described by Kodani et al. (2011) were
158 included on each TAC (21). A positive result was recorded if amplification occurred in at least
159 one of the duplicate or quadruplicate reactions with cycle threshold (Ct) <40.

160 Pathogen identification

161 The algorithm for pathogen identification is illustrated in Figure 1. Briefly; pathogen
162 identification was defined as: (A) detected in NP/OP and/or sputum for *Mycobacterium*
163 *tuberculosis*, *Mycoplasma pneumoniae*, *Bordetella* spp., *Legionella* spp., and all viruses, or (B)
164 detected in blood and/or sputum for *Streptococcus pneumoniae*, *Haemophilus influenzae*,
165 *Staphylococcus aureus*, *Klebsiella pneumoniae*, Group B streptococci (GBS), *Acinetobacter*
166 *baumannii* and *Pseudomonas aeruginosa*. The following pathogens were excluded from
167 analysis: cytomegalovirus (CMV) detected in blood as detection of the pathogen DNA in blood

168 cannot differentiate between latent and active disease (22), *S. aureus*, *S. pneumoniae*, *H.*
169 *influenzae*, *A. baumannii*, *K. pneumoniae*, *P. aeruginosa* and GBS if detected in NP/OP
170 specimens as these are common colonizers of the upper respiratory tract (12, 23-25), and *E.*
171 *coli/Shigella* spp. due to poor assay specificity (19, 20).

172 **Statistical analysis**

173 Stata 14 (Stata Corporation, College Station, TX) was used for statistical analysis. McNemar's χ^2
174 test or Fischer's exact test were used, where appropriate, to compare categorical variables (p-
175 value <0.05 was considered statistically significant). The positivity proportion of *S. pneumoniae*
176 in blood, *Bordetella* spp. in NP/OP and/or sputum specimens, and influenza A and B viruses, and
177 RSV in NP/OP specimens were compared between TAC and IRTP assays. Concordance between
178 the two tests was calculated using overall percent agreement (OPA). Agreement was further
179 defined using Cohen's *kappa* statistic (κ) which ranges between 0 and 1 in which $\kappa = 0$ indicates
180 no agreement and $\kappa = 1$ is perfect agreement (26).

181 **Ethics statement**

182 The national syndromic surveillance for pneumonia protocol (M140824) was approved by the
183 Human Research Ethics Committee (HREC) of the University of the Witwatersrand as well as the
184 local ethics committees of the respective sites. This surveillance was deemed non-research by
185 the Centers for Disease Control and Prevention, Atlanta, USA (U.S. CDC) and did not need
186 human subjects review by that institution. The protocol for the current study (M1902109) was
187 approved by the HREC of the University of the Witwatersrand.

188 **Availability of data**

189 All data generated or analysed during this study are included in this published article and its
190 supplementary information files.

191

192 **Results**

193 **Study population**

194 From January to December 2017, 956 patients were enrolled in the surveillance study at the
195 two sentinel sites and of these, 637 were selected for testing using TAC (Table 1). The median
196 age of the patients tested on TAC was 33 years (interquartile range (IQR) 6-47 years), and 24%
197 (154/637) were aged <5 years. SRI presentation was acute in 45% (286/637) of the patients, and
198 58% (369/637) were HIV-infected. The median duration of symptoms was 6 days (IQR 2-18
199 days). The case-fatality ratio was 7% (42/624) amongst the SRI patients with specimens tested
200 using TAC.

201 **Respiratory pathogens detected using TAC**

202 Among the 637 patients who were tested using TAC, 637 had blood tested, 487 had NP/OP
203 tested and, 411 had sputum tested. At least one pathogen was detected in 83% (527/637) of
204 patients: any bacterial pathogen in 67% (427/637) and any viral pathogen in 47% (302/637).
205 Among all SRI patients, common pathogens detected included *H. influenzae* (225/637; 35%), *S.*
206 *pneumoniae* (224/637; 35%), rhinovirus (144/637; 23%), *S. aureus* (129/637; 20%), *K.*

207 *pneumoniae* (85/637; 13%), *M. tuberculosis* (75/637; 12%), and RSV (57/637; 9%) (Tables 2 and
208 S2).

209 When comparing pathogen prevalence by age, with the exception of *K. pneumoniae* and *A.*
210 *baumannii*, bacterial pathogens were more prevalent in the older children aged ≥ 5 years and
211 adults compared to the young children aged < 5 years (72% [347/483] vs 52% [80/154]; p
212 < 0.001) (Fig 2) (Table 3). In contrast, *K. pneumoniae* at (19% [30/154] vs 11% [55/483]; $p = 0.01$
213 and *A. baumannii* at 10% [16/154] vs 4% [21/483]; $p = 0.005$ were more prevalent in the
214 younger children. The majority of the viral pathogens, with the exception of influenza B, were
215 also detected in the young children (77% [118/154] vs 38% [184/483]; $p < 0.001$). Influenza B
216 was only detected in the older children and adults at 4% (17/483).

217 Further, when comparing the prevalence of pathogens between HIV-infected and -uninfected
218 patients, it was found that bacterial pathogens were more commonly detected among HIV-
219 infected patients (74% [273/369] vs 57% [151/264]; $p < 0.001$) (Table 3). In contrast, the
220 prevalence of viral pathogens was higher among the HIV-uninfected patients (60% [158/264] vs
221 38% [141/369]; $p < 0.001$). Viral pathogens were more common among patients who presented
222 with acute SRI (56% [159/286] vs 41% [143/351]; $p < 0.001$) when compared to chronic SRI. In
223 contrast, bacterial pathogens were more common amongst the chronic cases (75% [263/351] vs
224 57% [164/286]; $p < 0.001$) when compared to acute SRI. Among patients with acute SRI, viral
225 pathogens were more common among the younger children (76% [96/127] vs 40% [63/159]; p
226 < 0.001) compared to older children and adults.

227 Pathogens were co-detected in 57% (364/637) of the patients, with up to 11 pathogens
228 detected in a single patient. The majority of these were bacterial-viral co-pathogens which were
229 detected in 32% (202/637) of the patients, ≥ 2 bacterial pathogens in 21% (137/637) and ≥ 2 viral
230 pathogens in 4% (25/637) (Fig 3). Pathogen co-detection rates were higher among HIV-infected
231 patients (61% [226/369] vs 52% [136/264] ; $p = 0.02$) and patients presenting with chronic SRI
232 (62% [217/351] vs 51% [147/286] ; $p = 0.01$) (Table 3). A pathogen was detected in 28 (67%)
233 patients among the 42 who died of which 43% (12/28) were bacterial-viral co-pathogens, 39%
234 (11/28) were bacterial and 18% (5/28) were viral pathogens. Pathogen co-detection rates were
235 lower among patients that survived compared to those that died, although not statistically
236 significant (68% [334/492] vs 82% [23/28]; $p = 0.17$).

237 Pathogens detected in blood specimens

238 A bacterial pathogen was detected in 48% (305/637) of blood specimens tested using TAC. *S.*
239 *pneumoniae* was the most frequently detected pathogen (80/637; 13%) while *K. pneumoniae*
240 (45/637; 7%), *S. aureus* (32/637; 5%), *H. influenzae* (23/637; 4%) and *A. baumannii* (19/637; 3%)
241 were also identified (Table 2). The detection rate of *S. pneumoniae* in young children (17/154;
242 11%) and older children and adults (63/483; 13%) was comparable ($p = 0.41$). While up to seven
243 bacterial pathogens were detected in a single blood specimen, ≥ 2 bacterial co-pathogens were
244 only detected in 11% (70/637) of patients (Fig 3).

245

246 Both a blood and sputum specimen were tested for 411 patients. Of the patients that tested
247 positive for *H. influenzae* in blood, 93% (13/14) had the same pathogen detected in sputum
248 (Table S3). A similar finding was noted for *S. pneumoniae* (39/54; 72%). In contrast, the rates of

249 positivity between blood and sputum specimens were lower for *S. aureus* (7/20; 30%), *K.*
250 *pneumoniae* (5/23; 22%) and *A. baumannii* (1/8; 13%). Similar trends were noted in the
251 positivity rates of these pathogens between blood and NP/OP among the 487 patients who had
252 both specimens tested using TAC (Table S3).

253

254 **Comparison between TAC and individual real-time PCR (IRTP)**

255 There was moderate agreement (OPA 91%; $\kappa=0.503$ [95% CI 0.392-0.614]) in the detection of *S.*
256 *pneumoniae* between the two assays, in which 34/90 (38%) of the *S. pneumoniae* detected in
257 634 bloods were detected on both platforms, 44/90 (49%) were detected using TAC only and
258 12/90 (13%) were detected on individual real-time PCR only (Table 4). There was substantial
259 agreement between the assays in the detection of *Bordetella* spp. in NP/OP (OPA 100%;
260 $\kappa=0.799$ [95% CI 0.413-1.000]) and in sputum (OPA 99%; $\kappa=0.618$ [95% CI 0.336-0.900]), and
261 almost perfect agreement for the detection of RSV (OPA 97%; $\kappa=0.837$ [95% CI 0.757-0.918]),
262 influenza A (OPA 99%; $\kappa=0.857$ [95% CI 0.745-0.970]) and influenza B (OPA 100%; $\kappa=0.748$ [95%
263 CI 0.411-1.000]) between the two assays. Discrepancies between the assays were noted in
264 specimens with low to medium pathogen load (Ct > 30), in which TAC yielded more pathogens
265 than IRTP (Table S4).

266

267 **Discussion**

268 We describe the use of a multi-pathogen real-time PCR platform, TAC, for the detection of
269 bacterial and viral pathogens in patients hospitalized with SRI at two sentinel sites in South

270 Africa from January to December 2017. At least one respiratory pathogen was detected in 83%
271 of the patients tested, in which bacterial and viral pathogen detections were 67% and 47%,
272 respectively. Overall, the most commonly detected pathogens included *S. pneumoniae*, *H.*
273 *influenzae*, rhinovirus, *S. aureus*, *K. pneumoniae*, *M. tuberculosis*, RSV, adenovirus, GBS, *P.*
274 *aeruginosa*, enterovirus, and *A. baumannii*.

275 Bacterial pathogens were more commonly detected in patients aged ≥ 5 years, HIV-infected
276 individuals and patients presenting with chronic symptoms. Among children aged < 5 years, *S.*
277 *pneumoniae* and *H. influenzae* were the two most prevalent bacterial pathogens, with 25% and
278 24% detection rates, respectively. Similar findings were reported by the Pneumonia Etiology
279 Research for Child Health (PERCH) study in which the detection of *S. pneumoniae* in lower
280 respiratory specimens was 24%-33% while *H. influenzae* (albeit non-type b) was detected at
281 16% in this age group (12). However, the detection of these pathogens in sputum specimens
282 can also be a result of contamination with upper respiratory tract flora due to poor specimen
283 collection practices. These high detection rates in our study, which were mostly in sputum, may
284 therefore be attributed to high carriage rates of these pathogens in the upper respiratory tract
285 of young children which can range from 7% - 93%, and 5% -70%, respectively, in low and middle
286 income countries (27). When restricted to blood specimens only in children < 5 years, the
287 detection rate of *S. pneumoniae* was 11% in our study. This 11% prevalence of *S. pneumoniae* in
288 the young children in our study is slightly higher than previously reported in South Africa, in
289 which the prevalence of *S. pneumoniae* was 4%-8% in blood tested using PCR alone or a
290 combination of PCR and culture (3, 12).

291 Our findings highlight potential roles for *S. aureus*, *K. pneumoniae*, *M. tuberculosis*, adenovirus,
292 GBS, enterovirus, *P. aeruginosa*, *A. baumannii*, and influenza A as important causes of SRI,
293 consistent with previous reports in South Africa, Niger and other African countries between
294 2010 and 2015 (12, 23, 24, 28, 29). The 12% detection rate of *M. tuberculosis* in our study, the
295 majority of which was detected among older children and adults, is in agreement with a
296 previous report in South Africa of 15% prevalence of the pathogen in patients aged >15 years
297 hospitalized with SRI between 2010 and 2011 (29). We also identified *S. aureus*, *K. pneumoniae*
298 and *A. baumannii* among the most commonly detected pathogens in agreement with a recent
299 report from the PERCH study as described above (12). In our study, while *K. pneumoniae* and *A.*
300 *baumannii* were more prevalent in young children, *S. aureus* was more prevalent among older
301 children and adults thus suggesting that these pathogens may play an important role in SRI in
302 these respective age groups.

303 Viral pathogen detections were more common in young children aged <5 years, HIV-uninfected
304 individuals, and in patients with acute SRI. We detected viruses in 77% of all SRI patients aged
305 <5 years, which is slightly higher than a recent finding by the PERCH study where viral
306 detections accounted for 61% (95% credible interval 57-66) of HIV-uninfected children aged <5
307 years hospitalized with SRI (12). However, this difference can be attributed to the difference in
308 the analytical approach for inference of SRI etiology as well as study design as in our study, we
309 tested both HIV-infected and -uninfected patients enrolled at only two surveillance sites in
310 South Africa (12). We also noted that the finding of 56% detection of a viral pathogen in our
311 acute SRI patients is lower than previously reported by Pretorius et al. (2016), who reported a
312 70% prevalence of viruses among patients of all ages hospitalized with acute SRI in South Africa

313 from 2012 to 2015 (30). This is likely due to different age distributions of the study populations
314 (73% were aged <5 years in study by Pretorius et al. compared to 24% in our study) as when
315 restricted to acute SRI patients aged <5 years in our study, viral detection was 76% in this age
316 group.

317 Rhinovirus and RSV were the most common viral pathogens detected in children aged <5 years
318 consistent with previous reports in the USA, Asia, South Africa and other African countries,
319 ranging from 31%-37% for RSV and 16%-28% for rhinovirus between 2009 and 2015 (12, 24, 31).
320 Rhinovirus was previously reported to have low attributable association (2-fold) with acute SRI
321 and high detection in asymptomatic controls in this age group in South Africa between 2012 and
322 2015 (30). In our study, rhinovirus was rarely detected as a sole pathogen in this age group (only
323 25% of all rhinovirus detections in children aged <5 years). Our finding of 25% RSV detection
324 rate in patients aged <5 years with SRI in South Africa is consistent with a previous report by
325 Cohen et al. (2015) who reported a 26% prevalence of RSV in this age group between 2009 and
326 2012 (3). Pretorius et al. (2016) previously reported a 10-fold odds of detection of RSV in acute
327 SRI cases compared to healthy controls in young children aged <5 years in South Africa between
328 2012 and 2015 thus highlighting a significant role of this pathogen in childhood SRI (30).

329 Pathogen co-detections of between two and 11 pathogens in a single patient accounted for 57%
330 of patients tested and were more commonly detected in HIV-infected individuals and patients
331 with chronic SRI. This complicates the ability to assign disease causality warranting further
332 research on the role of mixed infections in severe respiratory disease. Among patients with co-
333 infections, 32% had bacteria-virus, 21% bacteria-bacteria and 4% virus-virus co-detections. Co-

334 detections, especially bacterial-viral, have been reported to be associated with more severe
335 outcomes of SRI (32); in our study however, there was no difference in the rate of bacterial-viral
336 co-detections between the patients who died and those who survived however this may be due
337 to small numbers of patients with a fatal outcome.

338 TAC and individual real-time PCR assays were compared for the detection of *S. pneumoniae*,
339 *Bordetella* spp., influenza A and B and RSV A/B. We noted a substantial agreement between the
340 assays for the detection of the pathogens in specimens with higher pathogen load (using Ct
341 value as a proxy for pathogen load). However, in specimens with lower pathogen load, TAC
342 detected more pathogens than individual real-time PCR. As reported previously by Diaz et al.
343 (2013), our findings suggest that the increased number of replicates on TAC may have increased
344 the ability to detect pathogens with low pathogen load (19). However, other methodological
345 differences, such as blood pre-lysis, increased specimen volume, different TNA extraction
346 methods and PCR enzymes likely also contributed to improved TAC pathogen detection.

347 Overall, use of TAC for the detection of 21 pathogens in a single patient yielded a pathogen in
348 83% of the patients. Often, etiologic studies for the detection of pneumonia-causing pathogens
349 select, *a priori*, a panel of pathogens that are targeted by currently licensed vaccines or those
350 still in the pipelines as well as pathogens which are traditionally known causes of the disease
351 using conventional methods such as culture. Our findings therefore suggest that use of multi-
352 pathogen panels may be useful to understand the roles of other pathogens in SRI that may have
353 been traditionally underestimated as causes of SRI and which may be of public health
354 importance.

355 Limitations in our study included that we only considered *S. pneumoniae*, *S. aureus*, *K.*
356 *pneumoniae*, *H. influenzae*, *A. baumannii*, *P. aeruginosa* and GBS to be pathogens if detected in
357 blood and sputum specimens but excluded detection of these pathogens in NP/OP as they are
358 common colonizers of the upper respiratory tract and we could therefore not differentiate
359 between carriage and disease. This exclusion could have inadvertently resulted in the
360 underestimation of these pathogens. Conversely, detection of these pathogens in sputum can
361 also be a result of contamination with upper respiratory tract flora due to poor specimen
362 collection procedures and so may have overestimated the reported detection rates. Also,
363 detection of these pathogens in blood can be as a result of transient bacteremia and thus
364 further overestimating their role in SRI. Lastly, when comparing the performances of TAC and
365 individual real-time PCR for the detection of *S. pneumoniae*, *Bordetella* spp., influenza A and B
366 and RSV, we did not perform further verification of the discrepant results.

367 **Conclusion**

368 In our study, the use of a multi-pathogen real-time PCR platform yielded a pathogen in 83% of
369 the SRI patients. It also suggested potentially significant roles for non-vaccine preventable
370 pathogens such as RSV, *S. aureus* and *K. pneumoniae*, in childhood SRI. Surveillance activities
371 often monitor trends in the epidemiology of vaccine-preventable pathogens such as *S.*
372 *pneumoniae*, *Bordetella* spp., and influenza, however, our study suggests that monitoring of
373 other pathogens such as *S. aureus* and *K. pneumoniae* should be considered. These data could
374 be useful in informing future preventive or therapeutic public health interventions. Also, as

375 pathogen co-detections were common with the use of multi-pathogen tests, the clinical role of
376 these potential mixed infections in disease requires further investigation.

377

378 **Acknowledgements**

379 The authors would like to thank GERMS-SA for the study design, patient enrolment and data
380 collection; the Centre for Respiratory Diseases and Meningitis of the National Institute for
381 Communicable Diseases, a division of the National Health Laboratory Service for laboratory
382 testing and the U.S. CDC for the development and optimisation of the TaqMan Array Card
383 assays.

384 **Funding**

385 This work was supported by the U.S. CDC. The funders had no role in study design, data
386 collection, analysis and interpretation, decision to submit the work for publication, or
387 preparation of the manuscript.

388 **Authors' contributions**

389 MM performed the experiments, interpreted the results, organised the project and drafted the
390 manuscript. CR assisted with laboratory testing. NW supervised the project, interpreted the
391 results, and edited the manuscript. MdP, OH, EV, OM, KN, ST, SW, MW, CC and AvG assisted in
392 the study design and/or patient enrolment, interpreted the results, and edited the manuscript.
393 All authors contributed to manuscript revision, read and approved the submitted version. The
394 authors declare that they have no competing interests; CC has received grant support from
395 Sanofi Pasteur, Advanced Vaccine Initiative, and payment of travel costs from Parexel. NW and
396 AvG have received grant support from Sanofi Pasteur.

397

398

399

References

1. WHO. 2018. Global Health Estimates 2016: Disease burden by Cause, Age, Sex, by Country and by Region, 2000-2016, World Health Organisation, Geneva.
2. Lower R, I. 2018. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* 2018/09/19:1191-1210.
3. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, Hellferscee O, Dawood H, Chhagan M, Naby F, Haffeejee S, Variava E, Kahn K, Nzenze S, Tshangela A, von Gottberg A, Wolter N, Cohen AL, Kgokong B, Venter M, Madhi SA. 2015. Epidemiology of Viral-associated Acute Lower Respiratory Tract Infection Among Children <5 Years of Age in a High HIV Prevalence Setting, South Africa, 2009–2012. *Pediatr Infect Dis J* 34:66-72.
4. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, Hellferscee O, Dawood H, Haffeejee S, Variava E, Kahn K, Tshangela A, von Gottberg A, Wolter N, Cohen AL, Kgokong B, Venter M, Madhi SA. 2015. Epidemiology of Severe Acute Respiratory Illness (SARI) among Adults and Children Aged ≥ 5 years a High HIV-Prevalence Setting, 2009–2012. *PLoS ONE* 10:e0117716.
5. Leung E, Weil DE, Raviglione M, Nakatani H, World Health Organization World Health Day Antimicrobial Resistance Technical Working G. 2011. The WHO policy package to combat antimicrobial resistance. *Bulletin of the World Health Organization* 89:390-392.
6. Sacchi CT, Fukasawa LO, Gonzalves MG, Salgado MM, Shutt KA, Carvalhanas TR, Ribeiro AF, Kemp B, Gorla MCO, Albernaz RK, Marques EGL, Cruciano A, Waldman EA, Brandileone MC, Harrison LH, Team SÚPR-PSP. 2011. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in Sao Paulo, Brazil. *PLoS ONE* 2011/06/22:e20675-e20675.
7. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C, Society SAT, Africa FoIDSoS. 2017. South African guideline for the management of community-acquired pneumonia in adults. *J Thorac Dis* 9:1469-1502.
8. Levy ML, Le Jeune I, Woodhead MA, Macfarlaned JT, Lim WS, Group BTSCAPiAG. 2010. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. *Prim Care Respir J* 19:21-27.
9. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults, abstr *Clinical Infectious Diseases*, 3/1/2007.
10. Simusika P, Bateman AC, Theo A, Kwenda G, Mfula C, Chentulo E, Monze M. 2015. Identification of viral and bacterial pathogens from hospitalized children with severe acute respiratory illness in Lusaka, Zambia, 2011-2012: a cross-sectional study. *BMC Infect Dis* 15:52-52.
11. Velaphi SC, Westercamp M, Moleleki M, Pondo T, Dangor Z, Wolter N, von Gottberg A, Shang N, Demirjian A, Winchell JM, Diaz MH, Nakwa F, Okudo G, Wadula J, Cutland C, Schrag SJ, Madhi SA. 2019. Surveillance for incidence and etiology of early-onset neonatal sepsis in Soweto, South Africa. *PLoS One* 14:e0214077.
12. PERCH. 2019. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *Lancet* 2019/06/27:757-779.

13. Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L. 2016. Aetiology of childhood pneumonia in a well vaccinated South African birth cohort: a nested case-control study of the Drakenstein Child Health Study. *Lancet Respir Med* 4.
14. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, Dawood H, Chhagan M, Haffejee S, Variava E, Kahn K, Tshangela A, von Gottberg A, Wolter N, Cohen AL, Kgekong B, Venter M, Madhi SA. 2013. Severe Influenza-associated Respiratory Infection in High HIV Prevalence Setting, South Africa, 2009–2011. *Emerg Infect Dis* 19:1766-1774.
15. Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M. 2020. Antibiotic Susceptibility of NDM-Producing *Enterobacteriales* Collected in the United States in 2017 and 2018. *Antimicrobial Agents and Chemotherapy* 64:e00499-20.
16. Carvalho MG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW, Dagan R, Sampson JS. 2007. Evaluation and improvement of real-time PCR assays targeting *lytA*, *ply*, and *psaA* genes for detection of pneumococcal DNA. *J Clin Microbiol* 45:2460-2466.
17. Tatti KM, Sparks KN, Boney KO, Tondella ML. 2011. Novel multitarget real-time PCR assay for rapid detection of *Bordetella* species in clinical specimens. *J Clin Microbiol* 49:4059-4066.
18. McMorrow ML, Tempia S, Walaza S, Treurnicht FK, Moyes J, Cohen AL, Pretorius M, Hellferscee O, Wolter N, von Gottberg A, Nguweneza A, McAnerney JM, Naby F, Mekgoe O, Venter M, Madhi SA, Cohen C. 2019. The Impact of Human Immunodeficiency Virus Exposure on Respiratory Syncytial Virus-associated Severe Respiratory Illness in South African Infants, 2011–2016. *Clinical Infectious Diseases* doi:10.1093/cid/ciz288.
19. Diaz MH, Waller JL, Napoliello RA, Islam MS, Wolff BJ, Burken DJ, Holden RL, Srinivasan V, Arvay M, McGee L, Oberste MS, Whitney CG, Schrag SJ, Winchell JM, Saha SK. 2013. Optimization of Multiple Pathogen Detection Using the TaqMan Array Card: Application for a Population-Based Study of Neonatal Infection. *PLoS ONE* 8:e66183.
20. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, Schrag SJ, Taylor TH, Jr., Beall BW, Breiman RF, Feikin DR, Njenga MK, Mayer LW, Oberste MS, Tondella ML, Winchell JM, Lindstrom SL, Erdman DD, Fields BS. 2011. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. *J Clin Microbiol* 49:2175-2182.
21. Kodani M, Winchell JM. 2012. Engineered combined-positive-control template for real-time reverse transcription-PCR in multiple-pathogen-detection assays. *J Clin Microbiol* 50:1057-1060.
22. Larsson S, Soderberg-Naucler C, Wang FZ, Moller E. 1998. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. *Transfusion* 38:271-278.
23. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L. 2015. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults, abstr *New England Journal of Medicine*, 7/14/2015. Massachusetts Medical Society,
24. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, Zhu Y, Patel A, Hymas W, Chappell JD, Kaufman RA, Kan JH, Dansie D, Lenny N, Hillyard DR, Haynes LM, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Wunderink RG, Edwards KM, Pavia AT, McCullers JA, Finelli L, Team ftCfDCaPCEoPitCES. 2015. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. *N Engl J Med* 372:835-845.

25. Milucky J, Pondo T, Gregory CJ, Iuliano D, Chaves SS, McCracken J, Mansour A, Zhang Y, Aleem MA, Wolff B, Whitaker B, Whistler T, Onyango C, Lopez MR, Liu N, Rahman MZ, Shang N, Winchell J, Chittaganpitch M, Fields B, Maldonado H, Xie Z, Lindstrom S, Sturm-Ramirez K, Montgomery J, Wu K-H, Van Beneden CA, the Adult TACWG. 2020. The epidemiology and estimated etiology of pathogens detected from the upper respiratory tract of adults with severe acute respiratory infections in multiple countries, 2014–2015. *PLOS ONE* 15:e0240309.
26. Landis JR. 1977. The measurement of observer agreement for categorical data. *Biometrics* 36:207-216.
27. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, Greenwood BM. 2014. Carriage of *Streptococcus pneumoniae* and Other Respiratory Bacterial Pathogens in Low and Lower-Middle Income Countries: A Systematic Review and Meta-Analysis. *PLOS ONE* 9:e103293.
28. Lagare A, Ousmane S, Dano ID, Issaka B, Issa I, Mainassara HB, Testa J, Tempia S, Mamadou S. 2019. Molecular detection of respiratory pathogens among children aged younger than 5 years hospitalized with febrile acute respiratory infections: A prospective hospital-based observational study in Niamey, Niger. *Health Science Reports* 2:e137.
29. Walaza S, Tempia S, Dawood H, Variava E, Moyes J. 2015. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. *BMC Infect Dis* 15.
30. Pretorius MA, Tempia S, Walaza S, Cohen AL, Moyes J, Variava E, Dawood H, Seleka M, Hellferscee O, Treurnicht F, Cohen C, Venter M. 2016. The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenza-like illness in a population with a high HIV sero-prevalence, South Africa 2012-2015. *J Clin Virol* 2015/12/19:21-26.
31. Famoroti T, Sibanda W, Ndung'u T. 2018. Prevalence and seasonality of common viral respiratory pathogens, including Cytomegalovirus in children, between 0-5 years of age in KwaZulu-Natal, an HIV endemic province in South Africa. *BMC Pediatr* 18:240-240.
32. Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, Hernández I, Royo G, Martín-Hidalgo A. 2005. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology 24:377-383.

Tables and Figures

Table 1: Demographic and clinical characteristics of severe respiratory illness (SRI) patients enrolled at two sentinel sites in South Africa, January – December 2017

| Characteristic | All patients (N=956) n (%) | Tested on TAC (N=637) n (%) |
|---------------------------------|---------------------------------------|--|
| Gender | | |
| Female | 474 (50) | 319 (50) |
| Age in years | | |
| Median age (IQR) | 28 (1-44) | 33 (6-47) |
| Age group in years | | |
| <1 | 232 (24) | 83 (13) |
| 1-4 | 129 (13) | 71 (11) |
| 5-14 | 39 (4) | 24 (4) |
| 15-24 | 45 (5) | 36 (6) |
| 25-44 | 294 (31) | 242 (38) |
| 45-64 | 169 (18) | 143 (22) |
| ≥65 | 48 (5) | 38 (6) |
| Site province | | |
| Mpumalanga | 335 (35) | 176 (28) |
| North-West | 621 (65) | 461 (72) |
| Disease presentation | | |
| Acute SRI | 480 (50) | 286 (45) |
| Chronic SRI | 476 (50) | 351 (55) |
| HIV status | | |
| HIV infected | 468 (49) | 369 (58) |
| HIV uninfected | 478 (50) | 264 (41) |
| Unknown | 10 (1) | 4 (1) |
| Case fatality | 51/937 (5) | 42/624 (7) |
| Symptom duration in days | | |
| Median duration (IQR) | 4 (2-15) | 6 (2-18) |

Chronic SRI defined as ≥10 days symptom duration

Table 2: Bacterial and viral pathogens detected in patients hospitalized with severe respiratory illness by specimen type, at two sentinel sites in South Africa, January – December 2017

| Pathogen | All specimen types (N=637) | NP/OP specimens (N= 487) | Sputum specimens (N=411) | Blood (N=637) |
|------------------------|----------------------------|--------------------------|--------------------------|---------------|
| Bacteria | | | | |
| <i>H. influenzae</i> * | 225 (35) | NT | 215 (52) | 23 (4) |
| <i>S. pneumoniae</i> * | 224 (35) | NT | 183 (45) | 80 (13) |
| <i>S. aureus</i> * | 129 (18) | NT | 104 (25) | 32 (5) |
| <i>K. pneumoniae</i> * | 85 (13) | NT | 45 (11) | 45 (7) |
| <i>M. tuberculosis</i> | 75 (12) | 18 (4) | 66 (16) | NT |
| Group B streptococcus* | 47 (7) | NT | 35 (9) | 13 (2) |
| <i>A. baumannii</i> * | 37 (6) | NT | 19 (5) | 19 (3) |
| <i>P. aeruginosa</i> * | 33 (5) | NT | 23 (6) | 12 (2) |
| <i>Bordetella</i> spp. | 12 (2) | 3 (1) | 9 (2) | NT |
| <i>M. pneumoniae</i> | 11 (2) | 9 (2) | 5 (1) | NT |
| <i>Legionella</i> spp. | 8 (1) | 3 (1) | 5 (1) | NT |
| Viruses | | | | |
| Rhinovirus | 144 (23) | 119 (24) | 66 (16) | NT |
| RSV | 57 (9) | 54 (11) | 14 (3) | NT |
| Adenovirus | 47 (7) | 24 (5) | 30 (7) | NT |
| Enterovirus | 37 (6) | 34 (7) | 7 (2) | NT |
| Influenza A | 31 (5) | 25 (5) | 20 (5) | NT |
| hMPV | 20 (3) | 13 (3) | 8 (2) | NT |
| Influenza B | 17 (3) | 5 (1) | 15 (4) | NT |
| Parainfluenza 2 | 12 (2) | 11 (2) | 5 (1) | NT |
| Parainfluenza 1 | 7 (1) | 5 (1) | 4 (1) | NT |
| Parainfluenza 3 | 6 (1) | 3 (1) | 4 (1) | NT |

NP/OP, combined naso-and oro-pharyngeal specimen; hMPV, human metapneumovirus; RSV, respiratory syncytial virus; NT, not tested.

*For the respiratory TAC, these pathogens were regarded as positive if detected in sputum specimens (N=445).

Table 3: Prevalence of bacterial and viral pathogens, stratified by age, HIV status, and symptom duration, among patients hospitalized with severe respiratory illness, at two sentinel sites in South Africa, January – December 2017

| Pathogen | Prevalence of organism | | | | | | | | | |
|------------------------|------------------------|------------------|----------|------------------|--------------|----------------|------------------|-----------|-------------|------------------|
| | All patients | Age; n (%) | | p-value | HIV infected | HIV uninfected | p-value | Acute SRI | Chronic SRI | p-value |
| | | (N=369) | (N=264) | | (N=286) | (N=351) | | | | |
| n (%) | <5 years (N=154) | ≥5 years (N=483) | n (%) | n (%) | n (%) | n (%) | | | | |
| Any Bacteria | 427 (67) | 80 (52) | 347 (72) | <0.001 | 273 (74) | 151 (57) | <0.001 | 164 (57) | 263 (75) | <0.001 |
| <i>S. pneumoniae</i> * | 224 (35) | 39 (25) | 185 (38) | 0.003 | 149 (40) | 74 (28) | 0.001 | 78 (27) | 146 (42) | <0.001 |
| <i>H. influenzae</i> * | 225 (35) | 37 (24) | 188 (39) | <0.001 | 144 (39) | 78 (30) | 0.014 | 71 (25) | 154 (44) | <0.001 |
| <i>S. aureus</i> * | 129 (18) | 8 (12) | 111 (23) | 0.002 | 87 (24) | 42 (16) | 0.018 | 45 (16) | 84 (24) | 0.010 |
| <i>K. pneumoniae</i> * | 85 (13) | 30 (19) | 55 (11) | 0.010 | 43 (12) | 41 (16) | 0.156 | 45 (16) | 40 (11) | 0.109 |
| <i>M. tuberculosis</i> | 75 (12) | 5 (3) | 70 (14) | <0.001 | 55 (15) | 19 (7) | 0.003 | 19 (7) | 56 (16) | <0.001 |
| Group B streptococcus* | 47 (7) | 9 (6) | 38 (8) | 0.403 | 26 (7) | 21 (8) | 0.667 | 18 (6) | 29 (8) | 0.247 |
| <i>A. baumannii</i> * | 37 (6) | 16 (10) | 21 (4) | 0.005 | 21 (6) | 15 (6) | 0.996 | 23 (8) | 14 (4) | 0.030 |
| <i>P. aeruginosa</i> * | 33 (5) | 9 (6) | 24 (5) | 0.670 | 22 (6) | 11 (4) | 0.316 | 18 (6) | 15 (4) | 0.253 |
| Any virus | 302 (47) | 118 (77) | 184 (38) | <0.001 | 141 (38) | 158 (60) | <0.001 | 159 (56) | 143 (41) | <0.001 |
| Rhinovirus | 144 (23) | 53 (34) | 91 (19) | <0.001 | 70 (19) | 73 (28) | 0.010 | 78 (27) | 66 (19) | 0.011 |
| RSV | 57 (9) | 39 (25) | 18 (4) | <0.001 | 14 (4) | 43 (16) | <0.001 | 47 (16) | 10 (3) | <0.001 |
| Adenovirus | 48 (8) | 26 (17) | 22 (5) | <0.001 | 19 (5) | 29 (11) | 0.006 | 24 (8) | 24 (7) | 0.460 |
| Enterovirus | 37 (6) | 23 (15) | 14 (3) | <0.001 | 7 (2) | 30 (11) | <0.001 | 25 (9) | 12 (3) | 0.004 |
| Influenza A | 31 (5) | 8 (5) | 23 (5) | 0.828 | 13 (4) | 18 (7) | 0.058 | 10 (3) | 21 (6) | 0.147 |
| hMPV | 20 (3) | 7 (5) | 13 (3) | 0.251 | 10 (3) | 9 (3) | 0.611 | 7 (2) | 13 (4) | 0.366 |
| Influenza B | 17 (3) | 0 | 17 (4) | 0.018 | 15 (4) | 2 (1) | 0.011 | 4 (1) | 13 (4) | 0.073 |
| ≥2 pathogens | 364 (57) | 86 (56) | 278 (58) | 0.708 | 226 (61) | 136 (52) | 0.015 | 147 (51) | 217 (62) | 0.008 |

*For the respiratory TAC, these pathogens were regarded as positive if detected in sputum specimens. $P < 0.05$ considered statistically significant.

Table 4: Comparison of pathogens detected in patients hospitalized with severe respiratory illness using TaqMan Array Card (TAC) and individual real-time PCR

| Pathogen detected | Specimen type | IRTP + TAC+ | IRTP+ TAC- | IRTP- TAC + | Total + | IRTP- TAC- | OPA (%) | κ (95%CI) |
|------------------------|---------------|-------------|------------|-------------|---------|------------|---------|---------------------|
| <i>S. pneumoniae</i> | Blood | 34 | 12 | 44 | 90 | 544 | 91.17 | 0.503 (0.392-0.614) |
| <i>Bordetella</i> spp. | NP/OP | 2 | 0 | 1 | 3 | 481 | 99.79 | 0.799 (0.413-1.000) |
| | Sputum | 5 | 2 | 4 | 11 | 400 | 98.54 | 0.618 (0.336-0.900) |
| RSV | NP/OP | 44 | 5 | 10 | 59 | 428 | 96.92 | 0.837 (0.757-0.918) |
| Influenza A | NP/OP | 19 | 0 | 6 | 25 | 462 | 98.77 | 0.857 (0.745-0.970) |
| Influenza B | NP/OP | 3 | 0 | 2 | 5 | 482 | 99.59 | 0.748 (0.411-1.000) |

NP/OP, combined naso-and oro-pharyngeal specimen, IRTP, individual real-time PCR. RSV,

respiratory syncytial virus. +, positive. -, negative. OPA, overall percent agreement. κ , Cohen's

kappa statistic as a measure of agreement: 0.2 as slight agreement, 0.21-0.4 as fair, 0.41-0.60 as

moderate, 0.61-0.80 as substantial, and 0.81-1.00 almost perfect agreement.




Fig 1: Algorithm for pathogen identification in patients hospitalized with severe respiratory illness tested on TAC who were enrolled at two sentinel sites in South Africa between Jan and Dec 2017. We excluded the following from further analysis: (A) cytomegalovirus detected in blood as detection of the pathogen DNA in blood cannot differentiate between latent and active disease. (B) *S. aureus*, *S. pneumoniae*, *H. influenzae*, *A. baumannii*, *K. pneumoniae*, *P. aeruginosa* and Group B streptococci if detected in NP/OP specimens as these are common colonizers of the upper respiratory tract and, (C) *E. coli/Shigella* spp. due to poor assay specificity. hMPV, human metapneumovirus. PIV, parainfluenza.




Fig 2: Prevalence of pathogens detected among patients hospitalized with severe respiratory illness using TAC, stratified by age, January – December 2017




Fig 3: Co-detection of respiratory pathogens among patients hospitalized with severe respiratory illness at two sentinel sites in South Africa, January to December 2017